You are here: Industry Insights > Mallinckrodt

News List

Mallinckrodt to split business pharmatimes
December 10, 2018
UK-based specialty pharma group Mallinckrodt has unveiled plans to spin-off its specialty generics and active pharmaceutical ingredients business into a new company.
Mallinckrodt to spin off its speciality generics business next year pharmaceutical-technology
December 10, 2018
After two years of planning, UK-based pharmaceutical company Mallinckrodt has announced plans to split its speciality generics and active pharmaceutical ingredients (APIs) business....
Takeda-Shire votes, J&J-Legend and more—FiercePharmaAsia fiercepharma
December 10, 2018
Despite Mallinckrodt’s years-long effort to become a leading maker of innovative drugs, the U.K. company is best known for two of the industry’s biggest scandals.
Mallinckrodt’s Niemann-Pick Type C drug fails to hit trial target November 12, 2018
UK-based Mallinckrodt has revealed that its experimental therapy for Niemann-Pick Type C failed to hit targets in a recently completed registration trial.
FDA rejects Mallinckrodt's filing for jaundice therapy stannsoporfin firstwordpharma
August 23, 2018
Mallinckrodt on Wednesday confirmed that it received a complete response letter from the FDA regarding a filing seeking approval of stannsoporfin for use in newborns at risk of jaundice.
Mallinckrodt Initiates Nitric Oxide Gas Study americanpharmaceuticalreview
August 03, 2018
Mallinckrodt has initiated a company-sponsored, experimental, proof-of-concept study of nitric oxide gas with ex-vivo lung perfusion compared to lung perfusion alone in human lung transplants.....
Mallinckrodt gets two thumbs down from FDA for jaundice drug pharmafile
May 07, 2018
Mallinckrodt paid $80 million, with a further $345 million dependent on milestones, to acquire InfaCare in the hope that the latter’s treatment for jaundice in new-borns would gain a quick approval.
Suit Alleges Drug Impurity, Price Fixing as Mallinckrodt Shares Tumble biospace
April 16, 2018
Amid news of a whistleblower lawsuit, Mallinckrodt Pharmaceuticals (MNK:NYSE) shares dropped 9.51% yesterday.
Mallinckrodt subpoenaed, again, over sales of oxymorphone in growing opioid crisis fiercepharma
March 01, 2018
Mallinckrodt has received another subpoena seeking information about its sales of the powerful painkillers.
Mallinckrodt to Pay $1.2B for Sucampo Pharmaceuticals contractpharma
December 28, 2017
Mallinckrodt has announced it will acquire Sucampo Pharmaceuticals, including its commercial and development assets. The transaction was approved by the Boards of Directors of both companies.

Previous page 1 2 3 4 5 Next page